Eagle Health Investments LP Acquires Shares of 624,676 BioMarin Pharmaceutical Inc. $BMRN

Eagle Health Investments LP acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 624,676 shares of the biotechnology company’s stock, valued at approximately $35,744,000. BioMarin Pharmaceutical comprises about 5.9% of Eagle Health Investments LP’s holdings, making the stock its 5th biggest position. Eagle Health Investments LP owned 0.32% of BioMarin Pharmaceutical as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in BMRN. Rice Hall James & Associates LLC purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $14,203,000. Swedbank AB boosted its stake in shares of BioMarin Pharmaceutical by 70.6% in the fourth quarter. Swedbank AB now owns 796,737 shares of the biotechnology company’s stock valued at $47,350,000 after buying an additional 329,794 shares in the last quarter. LSV Asset Management boosted its stake in shares of BioMarin Pharmaceutical by 4.3% in the fourth quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company’s stock valued at $52,429,000 after buying an additional 36,700 shares in the last quarter. C WorldWide Group Holding A S grew its holdings in BioMarin Pharmaceutical by 12.6% during the fourth quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company’s stock worth $15,918,000 after acquiring an additional 30,000 shares during the period. Finally, Horizon Investments LLC grew its holdings in BioMarin Pharmaceutical by 22.3% during the fourth quarter. Horizon Investments LLC now owns 99,681 shares of the biotechnology company’s stock worth $5,924,000 after acquiring an additional 18,143 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The transaction gives BioMarin rights to ALE1, an oral therapy being developed for hypophosphatasia (HPP), a rare genetic bone disorder. The potential to offer a first oral treatment could address a significant unmet need and expand BioMarin’s presence in rare skeletal diseases. CNBC article
• Positive Sentiment: Investors and analysts see strategic and longer-term growth potential from adding ALE1 to BioMarin’s pipeline. Wedbush said the acquisition strengthens the company’s outlook, while BMO Capital Markets initiated coverage with an Outperform rating and a $98 price target, implying substantial upside from the referenced price. Barclays and Piper Sandler also issued bullish forecasts. Wedbush article
• Neutral Sentiment: The acquisition broadens BioMarin’s rare-disease portfolio, but ALE1 is still in early clinical trials. Its commercial value depends on successful development, regulatory approval and achievement of milestones, making the program a longer-term rather than immediate revenue driver. Alesta will also spin out its other assets before closing. BioMarin announcement
• Negative Sentiment: HC Wainwright lowered its price target from $60 to $59 and maintained a Neutral rating, while another analyst cut its target to $59. These targets suggest some investors believe the stock’s recent rise has outpaced near-term fundamentals and that execution and valuation risks remain. Analyst coverage

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BMRN shares. Barclays raised their target price on BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a report on Monday. HC Wainwright lowered their price target on shares of BioMarin Pharmaceutical from $60.00 to $59.00 and set a “neutral” rating on the stock in a research note on Tuesday. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Piper Sandler raised their price objective on shares of BioMarin Pharmaceutical from $82.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday. Finally, BMO Capital Markets initiated coverage on shares of BioMarin Pharmaceutical in a report on Wednesday. They set an “outperform” rating and a $98.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $88.83.

BioMarin Pharmaceutical Stock Up 3.5%

BioMarin Pharmaceutical stock opened at $69.33 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm has a market capitalization of $13.42 billion, a price-to-earnings ratio of 187.38, a price-to-earnings-growth ratio of 0.48 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The stock’s fifty day moving average is $60.21 and its two-hundred day moving average is $57.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter last year, the business posted $1.44 earnings per share. The business’s revenue for the quarter was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts predict that BioMarin Pharmaceutical Inc. will post 4.11 EPS for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.